Search

Your search keyword '"Lise Willems"' showing total 4 results
Start Over Author "Lise Willems" Publisher informa uk limited
4 results on '"Lise Willems"'

1. Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia

Author

Lise Willems, Nicolas Chapuis, Justine Decroocq, Lauriane Goldwirt, Didier Bouscary, Adrien Contejean, Jerome Tamburini, Jean Michel Cayuela, Jeremie Zerbit, and Rui Batista

Subjects
Niacinamide, Cancer Research, Lymphoblastic Leukemia, Fusion Proteins, bcr-abl, chemistry.chemical_compound, hemic and lymphatic diseases, Humans, Medicine, Philadelphia Chromosome, Protein Kinase Inhibitors, Philadelphia Chromosome Positive, ABL, business.industry, Ponatinib, Imidazoles, breakpoint cluster region, Hematology, Precursor Cell Lymphoblastic Leukemia-Lymphoma, respiratory tract diseases, Pyridazines, Oncology, chemistry, Cancer research, Pyrazoles, business, Tyrosine kinase
Abstract

Since the development of tyrosine kinase inhibitors (TKIs) targeting BCR/ABL1 and significantly improved outcomes on long-term disease-free survival in Philadelphia chromosome–positive (Ph+) acute ...

Published
2021
Full Text
View/download PDF

2. High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah’s Witnesses patients: a feasible option in the age of hematopoietic growth factors

Author

Eric Grignano, Benedicte Deau-Fischer, Adrien Contejean, Lise Willems, Lauris Gastaud, Didier Bouscary, Jerome Tamburini, Louis Perol, Marielle Legoff, and Patricia Franchi

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Lymphoblastic Leukemia, Philadelphia Chromosome Negative, food and beverages, Combination chemotherapy, Hematology, B-cell acute lymphoblastic leukemia, Philadelphia chromosome, medicine.disease, 03 medical and health sciences, Haematopoiesis, High dose chemotherapy, 0302 clinical medicine, hemic and lymphatic diseases, 030220 oncology & carcinogenesis, Internal medicine, medicine, Young adult, business, 030215 immunology
Abstract

B-cell acute lymphoblastic leukemia (B-ALL) can be cured in most children and in the majority of young adults with sufficiently intensive – and myelosuppressive – combination chemotherapy regimens ...

Published
2019
Full Text
View/download PDF

3. Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy

Author

Valérie Dumaine, Antoine Babinet, Philippe Anract, Emmanuelle Le Ray, Lisa Belin, Bénédicte Deau Fischer, Thierry Facon, Xavier Leleu, Didier Bouscary, Lise Willems, Jerome Tamburini, Leonardo Magro, Corine Plancher, and Youlia M. Kirova

Subjects
Male, 0301 basic medicine, Cancer Research, Pathology, medicine.medical_specialty, medicine.medical_treatment, Treatment outcome, Plasma cell dyscrasia, Bone Neoplasms, Kaplan-Meier Estimate, macromolecular substances, 03 medical and health sciences, 0302 clinical medicine, immune system diseases, Positron Emission Tomography Computed Tomography, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Combined Modality Therapy, Positron Emission Tomography-Computed Tomography, business.industry, Hematology, medicine.disease, Radiation therapy, Treatment Outcome, 030104 developmental biology, Oncology, Proteasome, 030220 oncology & carcinogenesis, Female, Radiotherapy, Intensity-Modulated, Intensity modulated radiotherapy, Radiology, business, Proteasome Inhibitors, Solitary plasmacytoma, Plasmacytoma
Abstract

We would like to report a study on solitary plasmacytoma of the bone (SPB) treatment.SPB is a rare plasma cell dyscrasia characterized by a single bone tumor with no evidence of other lesions or mu...

Published
2017
Full Text
View/download PDF

4. Successful treatment of<scp>l</scp>-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors

Author

Hélène Fontaine, Laurence Moachon, Jerome Tamburini, Philippe Sogni, Lise Willems, Chadi Al-Nawakil, Mona Benm’rad, Cédric Mauprivez, Benoit Terris, Didier Bouscary, and Benjamin Laffy

Subjects
Drug, Cancer Research, Asparaginase, animal structures, biology, Lymphoblastic Leukemia, media_common.quotation_subject, Hematology, Pharmacology, Cofactor, L asparaginase, chemistry.chemical_compound, Oncology, chemistry, hemic and lymphatic diseases, biology.protein, Asparagine, media_common
Abstract

l-asparaginase (L-ase) is a major drug used to treat acute lymphoblastic leukemia (ALL) [1]. L-ase kills leukemic cells by depleting circulating asparagine pools related to its asparaginase activit...

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results